Core Viewpoint - Xishan Technology (688576.SH) is facing significant challenges with declining revenue and profits, prompting investor concerns and discussions about the company's future strategies and stock buyback practices [1][2][3] Group 1: Company Overview - Xishan Technology, headquartered in Chongqing, specializes in surgical power devices, endoscopic systems, and energy surgical equipment, serving various clinical departments [1] - The company went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 6, 2023, with a strategic placement of shares [1] Group 2: Financial Performance - In 2024, Xishan Technology reported a revenue of 336 million yuan, a year-on-year decrease of 6.74%, and a net profit of 71.71 million yuan, down 22.45% [1] - For Q1 2025, the company generated revenue of 65.88 million yuan, a decline of 11.2% year-on-year, and a net profit of 8.99 million yuan, down 55.02% [2] Group 3: Investor Concerns - Investors have expressed concerns regarding the company's continuous revenue decline and significant profit drops since its IPO, questioning the effectiveness of the company's strategies to reverse this trend [2][3] - Xishan Technology has conducted multiple share buybacks, totaling approximately 490 million yuan, which has not positively impacted the stock price, leading to further investor dissatisfaction [3] Group 4: Stock Performance - As of June 9, 2025, Xishan Technology's stock price was 64.55 yuan per share, representing a decline of about 52.4% from its initial offering price of 135.80 yuan [3]
西山科技部分限售股解禁 上市两年已斥资近5亿回购股份